Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 359 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zyban Clear all

Conditions: Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
Interventions: Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination); Behavioral · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Tobacco Use Disorder
Interventions: Behavioral and pharmacologic tobacco use intervention; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Endometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer
Interventions: Weight loss with pharmacotherapy, Weight loss without pharmacotherapy; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: PTSD, Smoking
Interventions: Bupropion, nicotine replacement therapy, Smoking cessation counseling, mobile contingency management, Stay Quit Coach; Drug · Other · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Depressive Disorder
Interventions: Extended-release Bupropion Hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 48
States / cities: Anchorage, Alaska • Hamden, Connecticut • Newark, Delaware + 41 more

Conditions: Coronary Artery Disease
Interventions: Medical/Behavioral therapy, Standard of Care, Registry; Other
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia

Conditions: Tobacco Use Disorder
Interventions: Bupropion, Bupropion + Naltrexone; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Human Immunodeficiency Virus, Smoking
Interventions: Bupropion, Varenicline, Cognitive Behavioral Therapy, Nicotine Replacement Therapy, Relapse Prevention Text Messaging; Drug · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cancer and Tobacco Abuse
Interventions: Bupropion and intensive behavioral therapy; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Smoking Cessation
Interventions: placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 4,595 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 65
States / cities: Mobile, Alabama • Encino, California • Escondido, California + 54 more

Conditions: Binge-Eating Disorder, Obesity
Interventions: NB medication (Naltrexone Bupropion combination), Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Depression
Interventions: Sertraline, Placebo, BupropionXL; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 296 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 4
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 1 more

Conditions: Schizophrenia, Cigarette Smoking
Interventions: Nicotine replacement therapy, Bupropion, cognitive-behavioral smoking cessation counseling, Mobile Contingency Management, Stay Quit Coach, SMS text messaging; Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Smoking Cessation, Smoking, Tobacco, Mental Illness, Tobacco Use Disorder
Interventions: Videogame-based physical activity, Sedentary videogame, Bupropion, Counseling; Behavioral · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Treatment Resistant Depression, Major Depressive Disorder
Interventions: AXS-05, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 20
States / cities: Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more

Conditions: Drug-Interactions
Interventions: ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail, Cohort 3 Probe Cocktail; Drug · Combination Product
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: Abrika Bupropion 150 mg Extended-Released Tablet, Wellbutrin SR® 150 mg Extended-Release Tablet, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Nicotine Dependence
Interventions: bupropion SR; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 14 Years to 17 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2003
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Nicotine Dependence
Interventions: Varenicline Standard Protocol, Nicotine Patch Standard Protocol, Varenicline Adaptive Protocol, Nicotine Adaptive Protocol; Behavioral · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: MDD
Interventions: Wellbutrin SR 300Mg Extended-Release Tablet; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Smoking
Interventions: nicotine replacement therapy and bupropion, smoking cessation counseling and referrals; Drug · Behavioral
Lead sponsor: Atlantic Health System; Other
Eligibility: 21 Years and older
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke
Interventions: Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Usual Care; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Methamphetamine Use Disorder
Interventions: naltrexone plus bupropion; Drug
Lead sponsor: Walter Ling; Other
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Los Angeles, California • Honolulu, Hawaii • Dallas, Texas

Conditions: Obesity, Overweight
Interventions: WW Clinic, Bupropion-Naltrexone, Bupropion-Naltrexone-Metformin; Behavioral · Drug
Lead sponsor: WW International Inc; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

Tobacco Use Intervention Among Radiation Oncology Patients

Weight Loss Management in Endometrial Cancer Survivors

Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD

Seasonal Affective Depression (SAD) Study

The Precision CAD Trial

Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation

Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)

A Feasibility Study of Smoking Cessation Program in Radiation Oncology

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy

Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression

Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness

Mechanistic Evaluation of Response in TRD (MERIT)

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions

Bupropion Treatment for Youth Smoking Cessation

Adaptive Pharmacotherapy for Smoking Cessation

Effect of Bupropion on Seizure Threshold in Depressed Patients

Smoking Cessation Program: A Quality Improvement Trial in a Resident-Based Outpatient Clinic

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder

A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)